Clinical Trial Update: A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial comparing pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2 Positive Metastatic Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN